A detailed history of Byrne Asset Management LLC transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Byrne Asset Management LLC holds 1,500 shares of AUTL stock, worth $3,375. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,500
Previous 1,800 16.67%
Holding current value
$3,375
Previous $11,000 54.55%
% of portfolio
0.0%
Previous 0.01%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 23, 2024

SELL
$3.33 - $5.68 $999 - $1,704
-300 Reduced 16.67%
1,500 $5,000
Q1 2024

Apr 22, 2024

SELL
$5.39 - $7.29 $4,851 - $6,561
-900 Reduced 33.33%
1,800 $11,000
Q4 2023

Jan 29, 2024

BUY
$2.13 - $6.63 $5,751 - $17,901
2,700 New
2,700 $17,000

Others Institutions Holding AUTL

About Autolus Therapeutics plc


  • Ticker AUTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 90,909,800
  • Market Cap $205M
  • Description
  • Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...
More about AUTL
Track This Portfolio

Track Byrne Asset Management LLC Portfolio

Follow Byrne Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Byrne Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Byrne Asset Management LLC with notifications on news.